Zimmer Biomet’s (ZBH) Buy Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets reiterated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Tuesday morning. They currently have a $142.00 price objective on the medical equipment provider’s stock.

ZBH has been the subject of a number of other research reports. Royal Bank of Canada cut their price target on Zimmer Biomet to $125.00 and set an outperform rating for the company in a research note on Tuesday, November 7th. Zacks Investment Research downgraded Zimmer Biomet from a hold rating to a sell rating in a research note on Monday, November 6th. Jefferies Group restated a buy rating and issued a $136.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Deutsche Bank upgraded Zimmer Biomet from a hold rating to a buy rating and set a $128.00 target price on the stock in a research note on Tuesday, November 14th. Finally, Edward Jones upgraded Zimmer Biomet from a hold rating to a buy rating in a research note on Thursday, November 9th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Zimmer Biomet has an average rating of Hold and a consensus target price of $134.05.

Zimmer Biomet (NYSE:ZBH) opened at $115.24 on Tuesday. The stock has a market capitalization of $22,984.75, a PE ratio of 14.07, a price-to-earnings-growth ratio of 1.76 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a 12 month low of $100.87 and a 12 month high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet’s revenue for the quarter was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $1.79 EPS. equities research analysts expect that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. CWA Asset Management Group LLC lifted its stake in Zimmer Biomet by 1.8% in the second quarter. CWA Asset Management Group LLC now owns 1,952 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 34 shares during the last quarter. Advisory Services Network LLC lifted its stake in Zimmer Biomet by 1.0% in the second quarter. Advisory Services Network LLC now owns 3,690 shares of the medical equipment provider’s stock valued at $474,000 after purchasing an additional 37 shares during the last quarter. Armor Investment Advisors LLC lifted its stake in Zimmer Biomet by 2.0% in the second quarter. Armor Investment Advisors LLC now owns 2,600 shares of the medical equipment provider’s stock valued at $334,000 after purchasing an additional 50 shares during the last quarter. Geneva Advisors LLC lifted its stake in Zimmer Biomet by 2.7% in the second quarter. Geneva Advisors LLC now owns 2,107 shares of the medical equipment provider’s stock valued at $271,000 after purchasing an additional 55 shares during the last quarter. Finally, Sandy Spring Bank lifted its stake in Zimmer Biomet by 5.4% in the second quarter. Sandy Spring Bank now owns 1,288 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 66 shares during the last quarter. Institutional investors and hedge funds own 86.24% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Zimmer Biomet’s (ZBH) Buy Rating Reaffirmed at BMO Capital Markets” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/16/zimmer-biomets-zbh-buy-rating-reaffirmed-at-bmo-capital-markets.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply